http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-1905875-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3d028fd0f3b6f4abe7f3524a779018d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4873 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 1969-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_271e838748fd4aa82559009e7cf9ef8c |
| publicationDate | 1970-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-1905875-A1 |
| titleOfInvention | Means, produced by the combination of different chemical bodies, which regulates and prematurely induces menstrual bleeding and in menopausal menstruation induces the menstruation again after a standstill and prolongs it for several years |
| abstract | Preparation for regulation of menstruation and its continuation for several years after normal menopause consists of 4-methylvaleric acid, cinchonic acid lactone, 5-hydroxytryptamine, tryptophane, 2-hydroxyethylhydrazine, pentanone, trans-p-hydroxycinnamic acid, bromelin, methyl 3-methyl tiopropionate, N-(2-hydroxy-1-methylethyl)-d(+)lysergamide, and 17alpha-ethinyl-5-methoxyoestra-1,3,5(10)-triene-17beta-ol. The preparation is applied in capsules once or twice every 2-3 days prior to menstruation. The product reduces the gestagenic count, regulates menstruation and often eliminates the need for dilation curettage operations. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7955626-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8372449-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6964784-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8372448-B2 |
| priorityDate | 1969-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.